Yvon van Delft

926 total citations
28 papers, 481 citations indexed

About

Yvon van Delft is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Yvon van Delft has authored 28 papers receiving a total of 481 indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Infectious Diseases, 24 papers in Virology and 8 papers in Epidemiology. Recurrent topics in Yvon van Delft's work include HIV/AIDS drug development and treatment (25 papers), HIV Research and Treatment (24 papers) and HIV/AIDS Research and Interventions (15 papers). Yvon van Delft is often cited by papers focused on HIV/AIDS drug development and treatment (25 papers), HIV Research and Treatment (24 papers) and HIV/AIDS Research and Interventions (15 papers). Yvon van Delft collaborates with scholars based in Netherlands, United Kingdom and Germany. Yvon van Delft's co-authors include Christiane Moecklinghoff, José Ramón Arribas, Mark Nelson, Nathan Clumeck, Andrew Hill, Andrew Hill, Federico Pulido, Thomas Stark, Andrzéj Horban and Jan Gerstoft and has published in prestigious journals such as PLoS ONE, AIDS and Journal of Antimicrobial Chemotherapy.

In The Last Decade

Yvon van Delft

27 papers receiving 474 citations

Peers

Yvon van Delft

VIROL

EPIDE

HEPAT

Naomi Givens United Kingdom

David Piontkowsky United States

Mark Becker United States

Awny Farajallah United States

Miguel Goicoechea United States

Alberto Arranz Spain

Romina Quercia United Kingdom

Corine Chazallon France

Elisabeth H. Gisolf Netherlands

Ian McGowan United States

Naomi Givens United Kingdom

Yvon van Delft

566 ×1.3

399 ×1.1

VIROL

200 ×1.5

107 ×1.4

EPIDE

28 ×1.0

HEPAT

Citations per year, relative to Yvon van Delft Yvon van Delft (= 1×) peers Naomi Givens

Countries citing papers authored by Yvon van Delft

Since Specialization

Citations

This map shows the geographic impact of Yvon van Delft's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yvon van Delft with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yvon van Delft more than expected).

Fields of papers citing papers by Yvon van Delft

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yvon van Delft. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yvon van Delft. The network helps show where Yvon van Delft may publish in the future.

Co-authorship network of co-authors of Yvon van Delft

This figure shows the co-authorship network connecting the top 25 collaborators of Yvon van Delft. A scholar is included among the top collaborators of Yvon van Delft based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yvon van Delft. Yvon van Delft is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Munderi, Paula, et al.. (2019). Switching at Low HIV-1 RNA into Fixed Dose Combinations: TDF/FTC/RPV is non-inferior to TDF/FTC/EFV in first-line suppressed patients living with HIV. Southern African Journal of HIV Medicine. 20(1). 949–949. 3 indexed citations

Geretti, Anna María, et al.. (2015). Efficacy of Once Daily Darunavir/Ritonavir in PI-Naïve, NNRTI-Experienced Patients in the ODIN Trial. AIDS Research and Treatment. 2015. 1–6. 2 indexed citations

Solomon, Ajantha, Surekha Tennakoon, Edwin Leeansyah, et al.. (2014). No Difference in the Rate of Change in Telomere Length or Telomerase Activity in HIV-Infected Patients after Three Years of Darunavir/Ritonavir with and without Nucleoside Analogues in the MONET Trial. PLoS ONE. 9(11). e109718–e109718. 11 indexed citations

Antinori, Andrea, José Ramón Arribas, Jan Fehr, et al.. (2014). The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV‐1 RNA below 50 copies/mL. Journal of the International AIDS Society. 17(4S3). 19525–19525. 15 indexed citations

Nelson, Mark, Andrew Hill, Yvon van Delft, & Christiane Moecklinghoff. (2014). Etravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials. AIDS Research and Treatment. 2014. 1–7. 6 indexed citations

Perri, Giovanni Di, Bruce Green, Glynn Morrish, et al.. (2013). Pharmacokinetics and Pharmacodynamics of Etravirine 400 mg Once Daily in Treatment-Naïve Patients. HIV Clinical Trials. 14(3). 92–98. 5 indexed citations

Girard, Pierre‐Marie, et al.. (2013). Can we stop CD4+ testing in patients with HIV-1 RNA suppression on antiretroviral treatment?. AIDS. 27(17). 2759–2763. 27 indexed citations

Geretti, Anna María, José Ramón Arribas, Erkki Lathouwers, et al.. (2013). Dynamics of Cellular HIV-1 DNA Levels Over 144 Weeks of Darunavir/Ritonavir Monotherapy Versus Triple Therapy in the MONET Trial. HIV Clinical Trials. 14(1). 45–50. 24 indexed citations

Kakuda, Thomas N., et al.. (2013). Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two‐panel, two‐way, two‐period, randomized trial. HIV Medicine. 14(7). 421–429. 15 indexed citations

10.

Stephan, Christoph, Andrew Hill, W. A. Sawyer, Yvon van Delft, & Christiane Moecklinghoff. (2012). Impact of baseline HIV‐1 RNA levels on initial highly active antiretroviral therapy outcome: a meta‐analysis of 12,370 patients in 21 clinical trials*. HIV Medicine. 14(5). 284–292. 22 indexed citations

11.

Orkin, Chloe, Mark Nelson, Christine Katlama, et al.. (2012). Changes in Patient-reported Neuropsychiatric Outcomes during the SENSE Trial: First-line Treatment with Two Nucleoside Analogues plus Etravirine or Efavirenz. 3(3). e113–e119. 4 indexed citations

12.

Arribas, José Ramón, Nathan Clumeck, Mark Nelson, et al.. (2012). The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV‐1 RNA copies/mL at baseline. HIV Medicine. 13(7). 398–405. 73 indexed citations

13.

Arribas, José Ramón, et al.. (2012). Predictors of long‐term HIV RNA suppression on darunavir/ritonavir monotherapy in the MONET trial. Journal of the International AIDS Society. 15(S4). 1–1. 1 indexed citations

14.

Pulido, Federico, Andrew Hill, Yvon van Delft, & Christiane Moecklinghoff. (2012). Impact of hepatitis C co-infection on response to antiretroviral treatment.. PubMed. 14(2). 124–31. 13 indexed citations

15.

Clumeck, Nathan, Dénes Bánhegyi, Wolfgang Schmidt, et al.. (2011). 96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baseline. Journal of Antimicrobial Chemotherapy. 66(8). 1878–1885. 41 indexed citations

16.

Winston, Alan, Gerd Fätkenheuer, José Ramón Arribas, et al.. (2010). Neuropsychiatric Adverse Events With Ritonavir-Boosted Darunavir Monotherapy in HIV-Infected Individuals: A Randomised Prospective Study. HIV Clinical Trials. 11(3). 163–169. 13 indexed citations

17.

Nelson, Mark, Hans-Jürgen Stellbrink, Daniel Podzamczer, et al.. (2010). A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population. AIDS. 25(3). 335–340. 30 indexed citations

18.

Arribas, José Ramón, Andrzéj Horban, Jan Gerstoft, et al.. (2009). The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS. 24(2). 223–230. 140 indexed citations

19.

Loutfy, Mona, Esteban Ribera, Éric Florence, et al.. (2009). Sustained HIV RNA suppression after switching from enfuvirtide to etravirine in the early access programme. Journal of Antimicrobial Chemotherapy. 64(6). 1341–1344. 3 indexed citations

20.

Florence, Éric, et al.. (2008). Antiretroviral treatment use and HIV-RNA suppression rates for 877 European patients in the etravirine expanded access programme. Journal of the International AIDS Society. 11(Suppl 1). P36–P36. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact